CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

[
CStone Announces Inclusion of Cejemly ® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
[og_img]
https://www.investing.com/news/press-releases/cstone-announces-inclusion-of-cejemly–sugemalimab-as-a-firstline-combination-therapy-for-nsclc-in-esmo-guideline-93CH-3857994


Investing.com